Sugi Predict

Sugi Predict / Compounds / SCHEMBL18865728

SCHEMBL18865728

SCHEMBL18865728

Cc1cnnn1-c1ccc(C#N)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.54
▸ MEN1 O00255 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ ALDH1A1 P00352 3/20 0.49
▸ MAPT P10636 2/20 0.49
▸ HPGD P15428 2/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ HSD11B1 P28845 1/20 0.46
▸ CYP2A6 P11509 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ CYP11B2 P19099 3/20 0.41
▸ CYP19A1 P11511 1/20 0.41
▸ CYP11B1 P15538 1/20 0.41
▸ XDH P47989 1/20 0.40
▸ AR P10275 1/20 0.40
▸ IDO1 P14902 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20097513 0.77 ALDH1A1 (0.55) ALDH1A1HSD11B1FLT3
SCHEMBL3760260 0.76 TSHR (0.59) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL1500290 0.75 TSHR (0.58) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL16100084 0.75 HSD11B1 (0.46) ALDH1A1MAPTHSD11B1KDM4ECYP11B2
SCHEMBL16099490 0.75 HSD11B1 (0.59) ALDH1A1MAPTHSD11B1CYP11B2CYP19A1
SCHEMBL23329191 0.73 TSHR (0.56) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL18865836 0.73 ALDH1A1 (0.43) ALDH1A1CYP2A6KDM4EL3MBTL1CYP11B2
SCHEMBL23328981 0.73 TSHR (0.56) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL16099572 0.73 MAPT (0.47) TSHRALDH1A1MAPTHPGDHSD11B1
SCHEMBL378335 0.71 SLC34A1 (0.57) ALDH1A1MAPTHPGDKDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025129135-A2 COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME EIKON THERAPEUTICS, INC. (US) 2025-06-19 — — WO disclosed
US-12043623-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-12043623-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-12043623-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-20220281869-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS FORMA THERAPEUTICS, INC. 2022-09-08 — — US disclosed
CN-114702495-A Purinones as ubiquitin-specific protease 1 inhibitors 福马治疗有限公司 2022-07-05 — — CN disclosed
CN-108473495-B Purinones as ubiquitin-specific protease 1 inhibitors 福马治疗有限公司 2022-04-12 — — CN disclosed
US-11161848-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2021-11-02 — — US disclosed
US-11161848-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2021-11-02 — — US disclosed
EP-3696181-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS Forma Therapeutics, Inc. (US) 2020-08-19 — — EP disclosed
US-10399980-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2019-09-03 — — US disclosed
US-10399980-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2019-09-03 — — US disclosed
US-10189841-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2019-01-29 — — US disclosed
US-10189841-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2019-01-29 — — US disclosed
US-20180339986-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS FORMA THERAPEUTICS, INC. 2018-11-29 — — US disclosed
EP-3377493-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS Forma Therapeutics, Inc. (US) 2018-09-26 — — EP disclosed
CN-108473495-A Purinones as ubiquitin-specific protease 1 inhibitors 福马治疗有限公司 2018-08-31 — — CN disclosed
US-20170145012-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS FORMA THERAPEUTICS, INC. 2017-05-25 — — US disclosed
US-20170145012-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS FORMA THERAPEUTICS, INC. 2017-05-25 — — US disclosed
US-20170145012-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS FORMA THERAPEUTICS, INC. 2017-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11161848-B2 Purinones as ubiquitin-specific protease 1 inhibitors USP1, UBA1, UBXN1 TSHR 3937/4885MEN1 1383/4885KMT2A 2234/4885
US-20180339986-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS USP1, UBA1, UBXN1 TSHR 3937/4885MEN1 1383/4885KMT2A 2234/4885
US-10189841-B2 Purinones as ubiquitin-specific protease 1 inhibitors USP1, UBA1, UBXN1 TSHR 3937/4885MEN1 1383/4885KMT2A 2234/4885
US-10399980-B2 Purinones as ubiquitin-specific protease 1 inhibitors USP1, UBA1, UBXN1 TSHR 3937/4885MEN1 1383/4885KMT2A 2234/4885
US-20170145012-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS USP1, UBA1, UBXN1 TSHR 3937/4885MEN1 1383/4885KMT2A 2234/4885
US-20220281869-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS USP1, UBA1, UBXN1 TSHR 3937/4885MEN1 1383/4885KMT2A 2234/4885
US-12043623-B2 Purinones as ubiquitin-specific protease 1 inhibitors USP1, UBA1, UBXN1 TSHR 3937/4885MEN1 1383/4885KMT2A 2234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.